UniQure shares tumble as Huntington's gene therapy shows reduced benefit over time

UniQure announced new follow-up data from its experimental gene therapy for Huntington's disease, indicating the treatment's effect may diminish with longer observation.

The additional year of data showed a waning benefit compared with earlier results, prompting concerns among investors and analysts about the therapy's potential.

Following the disclosure, UniQure's stock price fell sharply on Tuesday morning, reflecting market reaction to the less-optimistic efficacy outlook.